Edgewise Therapeutics is selling its lead asset and remaking itself as a cardiovascular company. The Boulder, Colorado biotech said Servier, the foundation-governed French group, will acquire sevasemten and Edgewise’s entire muscular dystrophy business for $1.55 billion in upfront cash, plus up to $1.1 billion in regulatory and commercial milestone payments — aggregate consideration of up to $2.65 billion.
Sevasemten is an investigational, oral, first-in-class fast skeletal myosin inhibitor designed to limit the muscle damage caused by absent or non-functional dystrophin. It is not approved by any regulator. It is being studied in late-stage trials in Becker and Duchenne muscular dystrophy and holds FDA orphan-drug, rare-pediatric-disease and fast-track designations, plus EMA orphan-drug designations — none of which is a marketing approval. Edgewise says that, if approved, it would be the first therapy indicated for Becker, a rare X-linked disorder affecting roughly 12,000 people across the U.S., EU-5 and Japan. No controlled efficacy has been demonstrated to date.
The pivotal read is still ahead. The GRAND CANYON Becker cohort is fully enrolled at 175 participants and, by design, powered at greater than 98% to show a statistically significant difference versus placebo, with top-line data expected in the fourth quarter of 2026 — after the deal is slated to close in the third quarter. No primary efficacy results have been posted; the company’s reference to “sustained disease stabilization” comes from the open-label MESA extension, where participants maintained stable North Star Ambulatory Assessment scores, not from a placebo-controlled endpoint.
Why Edgewise sells now
The cash recasts Edgewise around its cardiac sarcomere modulators. Management says proceeds, combined with existing cash, will fully fund EDG-7500 in hypertrophic cardiomyopathy (Phase 2) through potential approval, with EDG-15400 (HFpEF, Phase 1) and EDG-003 behind it. The company also reaffirmed plans to report 12-week data from Part D of the CIRRUS-HCM trial of EDG-7500 in the second quarter of 2026.
“This transaction delivers immediate, significant value… while placing sevasemten with an acquirer that has the global scale,” said CEO Kevin Koch.
For Servier, President Olivier Laureau framed the buy as “an immediate platform” in neuromuscular disease ahead of the group’s 2030 ambitions. The deal awaits Hart-Scott-Rodino clearance and is expected to close in the third quarter of 2026.